Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study. Izutsu K, Watanabe M, Toubai T, Tsukamoto T, et al. Int J Hematol 2026;123:225-232.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Izutsu K, Watanabe M, Toubai T, Tsukamoto T, et al. Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study. Int J Hematol 2026;123:225-232.
PMID: 41212498